[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0415636A - anidrato cristalino com efeito anticolinérgico - Google Patents

anidrato cristalino com efeito anticolinérgico

Info

Publication number
BRPI0415636A
BRPI0415636A BRPI0415636-6A BRPI0415636A BRPI0415636A BR PI0415636 A BRPI0415636 A BR PI0415636A BR PI0415636 A BRPI0415636 A BR PI0415636A BR PI0415636 A BRPI0415636 A BR PI0415636A
Authority
BR
Brazil
Prior art keywords
anticholinergic effect
crystalline anhydrate
anhydrate
preparation
treatment
Prior art date
Application number
BRPI0415636-6A
Other languages
English (en)
Inventor
Waldemar Pfrengle
Peter Sieger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34530662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415636(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0415636A publication Critical patent/BRPI0415636A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"ANIDRATO CRISTALINO COM EFEITO ANTICOLINéRGICO". A presente invenção refere-se a um novo anidrato cristalino do brometo de tiotrópio, processo para sua preparação bem como seu uso para preparação de um medicamento para o tratamento de doenças do trato respiratório, particularmente para o tratamento de COPD ('chronic obstructive pulmonary disease' = doença pulmonar obstrutiva crónica) e asma.
BRPI0415636-6A 2003-11-03 2004-10-29 anidrato cristalino com efeito anticolinérgico BRPI0415636A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025077 2003-11-03
PCT/EP2004/012269 WO2005042527A1 (de) 2003-11-03 2004-10-29 Neues kristallines anhydrat mit anticholinerger wirksamkeit

Publications (1)

Publication Number Publication Date
BRPI0415636A true BRPI0415636A (pt) 2006-12-12

Family

ID=34530662

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415636-6A BRPI0415636A (pt) 2003-11-03 2004-10-29 anidrato cristalino com efeito anticolinérgico

Country Status (34)

Country Link
EP (1) EP1682542B1 (pt)
JP (1) JP4553902B2 (pt)
KR (2) KR101285571B1 (pt)
CN (1) CN100509809C (pt)
AR (1) AR046319A1 (pt)
AT (1) ATE453641T1 (pt)
AU (1) AU2004285684B2 (pt)
BR (1) BRPI0415636A (pt)
CA (1) CA2544352C (pt)
CO (1) CO5690641A2 (pt)
CY (1) CY1110339T1 (pt)
DE (1) DE502004010602D1 (pt)
DK (1) DK1682542T3 (pt)
EA (1) EA008587B1 (pt)
EC (1) ECSP066543A (pt)
ES (1) ES2338563T3 (pt)
HK (1) HK1099752A1 (pt)
HR (1) HRP20100029T1 (pt)
IL (1) IL175126A (pt)
ME (1) ME00349B (pt)
MX (1) MX272045B (pt)
MY (1) MY146628A (pt)
NO (1) NO20062569L (pt)
NZ (1) NZ547581A (pt)
PE (1) PE20050996A1 (pt)
PL (1) PL1682542T3 (pt)
PT (1) PT1682542E (pt)
RS (2) RS20060291A (pt)
SI (1) SI1682542T1 (pt)
TW (1) TWI336330B (pt)
UA (1) UA82909C2 (pt)
UY (1) UY28596A1 (pt)
WO (1) WO2005042527A1 (pt)
ZA (1) ZA200602344B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080007656A (ko) * 2005-05-02 2008-01-22 베링거 인겔하임 인터내셔날 게엠베하 티오트로피움 브로마이드의 신규한 결정질 형태
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
WO2007075858A2 (en) * 2005-12-19 2007-07-05 Sicor Inc. Novel forms of tiotropium bromide and processes for preparation thereof
RU2453547C2 (ru) * 2005-12-19 2012-06-20 Сикор Инк. Новые формы тиотропия бромида и способы их получения
DE602006020620D1 (de) * 2006-01-04 2011-04-21 Boehringer Ingelheim Pharma Verwendung von tiotropium-salzen bei der behandlung von mässigem persistierendem asthma
CN100999521B (zh) * 2006-01-13 2010-12-08 江苏正大天晴药业股份有限公司 结晶性抗胆碱药噻托溴铵
US20080051582A1 (en) 2006-07-10 2008-02-28 Sicor Inc. Process for the preparation of tiotropium bromide
CN101032484B (zh) * 2007-04-02 2010-05-26 南京卡文迪许生物工程技术有限公司 一种噻托溴铵胶囊型吸入粉雾剂
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
WO2010052450A1 (en) * 2008-11-04 2010-05-14 Cipla Limited Tiotropium bromide having a low degree of crystallinity
BRPI0916047A2 (pt) * 2008-11-04 2015-11-10 Cipla Ltd composição farmacêutica em aerossol, uso de uma composição farmacêutica em aerossol, método para tratamento de sintomas crônicos ou agudos severos, moderados ou leves, ou para tratamento profilático de um distúrbio respiratório, dispensador farmacêutico em aerossol, processo para fabricação de um dispensador farmacêutico em aerossol e processo para fabricação de um complexo de um agente ativo e um adjuvante
CA2768553C (en) * 2009-08-07 2016-08-02 Generics [Uk] Limited Anhydrate of tiotropium bromide
TR201111589A2 (tr) * 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür susuz kristal formu.
CZ304368B6 (cs) 2011-11-28 2014-04-02 Zentiva, K.S. Směsný solvát tiotropium bromidu a způsob jeho přípravy
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2014042605A1 (en) * 2012-09-11 2014-03-20 Mahmut Bilgic New tiotropium bromide crystalline form
HUE032455T2 (en) 2012-11-05 2017-09-28 Zentiva Ks Stabilization of thiotropium solvates
EP2913332A1 (en) 2014-02-27 2015-09-02 Euticals S.P.A. Crystalline form of tiotropium bromide with lactose
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
WO2017138896A1 (en) 2016-02-11 2017-08-17 Sima Patent Ve Lisanslama Hizmetleri Ltd. Şti Crystalline form of tiotropium bromide anhydrate
EP4108230A1 (en) 2021-06-24 2022-12-28 Laboratoires SMB New dry powder composition of tiotropium for inhalation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP1326862B1 (de) * 2000-10-12 2004-09-15 BOEHRINGER INGELHEIM PHARMA GMBH &amp; CO. KG Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
IL159238A0 (en) * 2001-06-22 2004-06-01 Boehringer Ingelheim Pharma Crystalline anticholinergic, method for its production, and use thereof in the production of a drug

Also Published As

Publication number Publication date
ZA200602344B (en) 2007-07-25
KR101285571B1 (ko) 2013-07-15
TWI336330B (en) 2011-01-21
EP1682542B1 (de) 2009-12-30
ES2338563T3 (es) 2010-05-10
KR20060121131A (ko) 2006-11-28
DK1682542T3 (da) 2010-05-10
CN1875019A (zh) 2006-12-06
DE502004010602D1 (de) 2010-02-11
TW200526652A (en) 2005-08-16
EP1682542A1 (de) 2006-07-26
NO20062569L (no) 2006-07-12
HRP20100029T1 (hr) 2010-02-28
RS51599B (en) 2011-08-31
EA008587B1 (ru) 2007-06-29
IL175126A (en) 2010-11-30
MY146628A (en) 2012-09-14
SI1682542T1 (sl) 2010-04-30
MEP51708A (en) 2011-02-10
AU2004285684A1 (en) 2005-05-12
MXPA06004940A (es) 2006-07-20
AR046319A1 (es) 2005-11-30
UY28596A1 (es) 2005-06-30
PT1682542E (pt) 2010-01-27
MX272045B (en) 2009-11-23
KR101313904B1 (ko) 2013-09-30
CA2544352C (en) 2013-07-16
HK1099752A1 (en) 2007-08-24
CY1110339T1 (el) 2015-01-14
JP2007509894A (ja) 2007-04-19
UA82909C2 (en) 2008-05-26
EA200600853A1 (ru) 2006-10-27
KR20120036381A (ko) 2012-04-17
PL1682542T3 (pl) 2010-06-30
CO5690641A2 (es) 2006-10-31
JP4553902B2 (ja) 2010-09-29
IL175126A0 (en) 2006-09-05
ATE453641T1 (de) 2010-01-15
NZ547581A (en) 2009-03-31
WO2005042527A1 (de) 2005-05-12
CA2544352A1 (en) 2005-05-12
ME00349B (me) 2011-05-10
RS20060291A (en) 2008-06-05
CN100509809C (zh) 2009-07-08
AU2004285684B2 (en) 2011-07-14
PE20050996A1 (es) 2005-12-20
ECSP066543A (es) 2006-10-17

Similar Documents

Publication Publication Date Title
BRPI0415636A (pt) anidrato cristalino com efeito anticolinérgico
UY29506A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
EA200500715A1 (ru) Новые лекарственные средства для лечения хронического обструктивного заболевания лёгких
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
EA200401005A1 (ru) Дозированные ингаляторы под давлением, содержащие растворы бета-2-агонистов
PT1289506E (pt) Processo para a producao de uma composicao micronizada estavel de formoterol comum glucocorticosteroide
EA200500902A1 (ru) Порошковые лекарственные средства, содержащие соль тиотропия и ксинафоат салметерола
NO20032111L (no) Nye medikamentblandinger basert pa tiotropium-salter og pa salmeterol-salter
ECSP066545A (es) Procedimiento para la preparación de sales de tiotropio, sales de tiotropio, así como formulaciones medicamentosas que las contienen
BR0306663A (pt) Formulação de salmeterol superfino
HUP0400222A2 (hu) PDE-4 inhibitort és H1 receptor antagonistát tartalmazó kombináció és ennek alkalmazása tüdőbetegségek kezelésére alkalmas gyógyszerkészítmény előállítására
BRPI0416136A (pt) processo para a produção de sais de tiotrópio, sais de tiotrópio, bem como formulações de medicamentos contendo os mesmos
UY28096A1 (es) Nueva formulación pulveurlenta que contiene tiotropio destinada a la inhalación
MXPA05011059A (es) Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos.
BRPI0415685A (pt) sais de tiotrópio, processos para sua produção, bem como formulações de medicamentos contendo os mesmos
CY1113392T1 (el) Νεες κρυσταλλικες μορφες του βρωμιουχου τιοτροπιου

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.